DATA PLANS
Download historical data for 20 million indicators using your browser.
Subscription Plans
|
Features
API GATEWAY
Direct access to our data from your apps using any programing language.
Features
|
Documentation
Already a user?
Login
Light Mode
Dark Mode
Calendar
News
Markets
Currencies
Stocks
Commodities
Bonds
Crypto
Earnings
Holidays
Indicators
Inflation Rate
Interest Rate
Unemployment Rate
GDP Growth
GDP per Capita
GDP Value
Current Account
Credit Rating
Wages Growth
Gold Reserves
Government Debt
Crude Oil Production
Gasoline Prices
Heatmap Table
More Indicators
Countries
United States
China
Japan
Canada
Australia
Brazil
Russia
India
Euro Area
United Kingdom
Germany
France
Italy
Spain
Switzerland
Singapore
More Countries
Forecasts
Countries
Indicators
Currencies
Stocks
Commodities
Bonds
Crypto
Peregrine Pharmaceuticals | PPHM - Current Assets
Chart
Quotes
Financials
1Y
5Y
10Y
25Y
MAX
Chart
Column
Line
Area
Spline
Splinearea
Trend
Average(4)
Histogram
Variance
Mean
Maximum
Minimum
Compare
Export
API
Embed
Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.
Features
Questions?
Contact us
Already a Member?
Login
The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.
API Features
Documentation
Interested?
Click here to contact us
Please Paste this Code in your Website
width
height
Preview
Peregrine Pharmaceuticals
Peregrine Pharmaceuticals reported $132.34M in Current Assets for its fiscal quarter ending in December of 2022.
Current Assets
Change
Date
Agenus
AGEN:US
USD 205.69M
7.43M
Mar/2023
Amgen
AMGN:US
USD 44.7B
22.52B
Mar/2023
AstraZeneca
AZN:LN
USD 22.27B
327M
Mar/2023
Celldex Therapeutics
CLDX:US
USD 289.6M
28.1M
Mar/2023
Eli Lilly
LLY:US
USD 20.81B
2.78B
Mar/2023
GlaxoSmithKline
GSK:LN
GBP 19.72B
1.05B
Mar/2023
Immunogen
IMGN:US
USD 243.86M
60.26M
Mar/2023
Intrexon
XON:US
USD 137.74M
19.58M
Mar/2023
Karyopharm Therapeutics
KPTI:US
USD 318.54M
37.93M
Mar/2023
Lumos Pharma Inc.
NLNK:US
USD 63.25M
8.76M
Mar/2023
MacroGenics
MGNX:US
USD 288.94M
66.76M
Mar/2023
MannKind
MNKD:US
USD 223.3M
11.6M
Mar/2023
Minerva Neurosciences
NERV:US
USD 36.67M
3.48M
Mar/2023
Novartis
NOVN:VX
USD 32.11B
4.8B
Mar/2023
Novavax
NVAX:US
USD 971.03M
732.36M
Mar/2023
Peregrine Pharmaceuticals
PPHM:US
USD 132.34M
13.6M
Dec/2022
Repligen
RGEN:US
USD 1.02B
20.68M
Mar/2023
Roche Holding
ROG:VX
33.82B
3.5B
Dec/2022
Xencor
XNCR:US
USD 629.98M
45.37M
Mar/2023
Financials
Stock Price
Assets
Cash and Equivalent
Cost of Sales
Current Assets
Current Liabilities
Debt
EBIT
EBITDA
Employees
EPS Earnings Per Share
Equity Capital and Reserves
Gross Profit on Sales
Interest Expense on Debt
Interest Income
Loan Capital
Market Capitalization
Net Income
Operating Expenses
Operating Profit
Ordinary Share Capital
PE Price to Earnings
Pre-Tax Profit
Sales Revenues
Selling and Administration Expenses
Stock
Trade Creditors
Trade Debtors